Daniel Nebdal
Overview
Explore the profile of Daniel Nebdal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindemann K, Siegenthaler F, Lande K, Casas-Arozamena C, Nebdal D, Rau T, et al.
Gynecol Oncol
. 2025 Mar;
195:98-105.
PMID: 40081113
Objective: At present, no reliable blood-based biomarkers have been established for patients with endometrial cancer. Liquid biopsies, which can detect circulating tumor DNA (ctDNA), provide a non-invasive way to assess...
2.
Davidson B, Teien Lande K, Nebdal D, Nesbakken A, Holth A, Lindemann K, et al.
Virchows Arch
. 2024 Sep;
PMID: 39235515
The objective of the present study was to characterize the molecular features of endometrial carcinomas with ambiguous histology. Eighteen carcinomas that could not be conclusively typed based on morphology and...
3.
Ojlert A, Nebdal D, Snapkov I, Olsen V, Kidman J, Greiff V, et al.
Mol Oncol
. 2021 Aug;
15(11):2958-2968.
PMID: 34402187
Previous studies have indicated a synergistic effect between radiotherapy and immunotherapy. A better understanding of how this combination affects the immune system can help to clarify its role in the...
4.
Ojlert A, Nebdal D, Lund-Iversen M, Astrom Ellefsen R, Brustugun O, Gran J, et al.
Acta Oncol
. 2020 Dec;
60(2):149-156.
PMID: 33356733
Background: The implementation of immune checkpoint inhibitors (ICI) into the standard care of advanced non-small cell lung cancer (NSCLC) has improved prognosis for this group of patients. However, long-term survival...
5.
Tekpli X, Lien T, Rossevold A, Nebdal D, Borgen E, Ohnstad H, et al.
Nat Commun
. 2019 Dec;
10(1):5499.
PMID: 31796750
How mixtures of immune cells associate with cancer cell phenotype and affect pathogenesis is still unclear. In 15 breast cancer gene expression datasets, we invariably identify three clusters of patients...
6.
Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC
Halvorsen A, Aure M, Ojlert A, Brustugun O, Solberg S, Nebdal D, et al.
Mol Oncol
. 2019 Sep;
13(12):2604-2615.
PMID: 31505091
Dysregulation of microRNAs is a common mechanism in the development of lung cancer, but the relationship between microRNAs and expression subtypes in non-small-cell lung cancer (NSCLC) is poorly explored. Here,...
7.
Lindholm E, Aure M, Haugen M, Sahlberg K, Kristensen V, Nebdal D, et al.
Mol Oncol
. 2019 Aug;
13(10):2278-2296.
PMID: 31402562
One of the hallmarks of cancer is sustained angiogenesis. Favorable results have been reported in some breast cancer (BC) patients receiving antiangiogenic therapy with bevacizumab (Bev) in combination with chemotherapy,...
8.
Ojlert A, Halvorsen A, Nebdal D, Lund-Iversen M, Solberg S, Brustugun O, et al.
Mol Oncol
. 2019 Mar;
13(5):1166-1179.
PMID: 30854794
The impact of the tumor immune microenvironment on overall survival in non-small cell lung cancer (NSCLC) has been studied, but there is little information on its relevance for risk of...
9.
Lindholm E, Leivonen S, Undlien E, Nebdal D, Git A, Caldas C, et al.
Microrna
. 2018 Dec;
8(2):155-165.
PMID: 30520388
Background: HER2 positive Breast Cancers (BC) have aggressive behavior and poor prognosis. Previously, we have identified miR-342-5p as an upstream regulator of HER2 signaling, as well as inhibitor of HER2...
10.
Rye I, Trinh A, Saetersdal A, Nebdal D, Lingjaerde O, Almendro V, et al.
Mol Oncol
. 2018 Aug;
12(11):1838-1855.
PMID: 30133130
Targeted therapy for patients with HER2-positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor...